Welcome to our dedicated page for ASEP MED HLDGS news (Ticker: SEPSF), a resource for investors and traders seeking the latest updates and insights on ASEP MED HLDGS stock.
ASEP MED HLDGS INC (SEPSF) delivers cutting-edge solutions for antibiotic-resistant infections through AI-powered diagnostics and therapeutic innovations. This news hub provides investors and medical professionals with essential updates on the company’s progress in combating sepsis and biofilm-related diseases.
Access official press releases covering regulatory milestones, clinical trial outcomes, and strategic partnerships. Our curated news collection enables stakeholders to track developments in three core areas: rapid sepsis detection systems, next-generation antimicrobial peptides, and infection-prevention medical coatings.
Stay informed about SEPSF’s advancements in artificial intelligence applications for gene expression analysis and peptide optimization. The page consolidates critical updates including FDA submissions, research collaborations, and intellectual property developments relevant to healthcare providers and biotech investors.
Bookmark this resource for real-time updates on technologies reshaping infection management. Visit regularly to monitor SEPSF’s progress in addressing the global antibiotic resistance crisis through measurable scientific breakthroughs.
Asep Medical Holdings Inc. (OTCQB: SEPSF) announced a joint venture with Sansure Biotech Inc. on January 27, 2023, aimed at commercializing the SepsetER sepsis diagnostic kit in China. The agreement, signed on September 29, 2022, outlines collaboration terms for research, development, and sublicensing in the Chinese market. Sansure will invest capital and Asep will receive royalties on sales. With a high sepsis mortality rate in China, this partnership is positioned to offer advanced diagnostic solutions, enhancing early detection capabilities while potentially reducing antibiotic resistance.
Asep Medical Holdings Inc. (CSE: ASEP, OTCQB: SEPSF) announced an online webinar on January 24, 2023, at 1:00 pm EST, to discuss global market developments, scientific advances, and investment milestones. Key topics include updates on the acquisition of SafeCoat Medical Inc., a joint venture with Bahrain's Seaspring W.L.L., and advancements in their sepsis diagnostic test kit, SepsetME. The webinar will also cover a feasibility study for an antibacterial mouthwash in China and the development of new wound bandages. The company aims to address significant medical needs associated with antibiotic failure.
